ADC Therapeutics SA Unveils Corporate Presentation Highlighting ZYNLONTA Expansion and Progress on Next-Generation PSMA-Targeting ADC
Reuters
Sep 30
<a href="https://laohu8.com/S/ADCT">ADC Therapeutics SA</a> Unveils Corporate Presentation Highlighting ZYNLONTA Expansion and Progress on Next-Generation PSMA-Targeting ADC
ADC Therapeutics SA presented an update highlighting its progress in the field of antibody-drug conjugates (ADCs). The company reported continued commercialization of ZYNLONTA® for third-line or later diffuse large B-cell lymphoma (DLBCL), with potential expansion into earlier lines of therapy and additional indications, including follicular lymphoma (FL) and marginal zone lymphoma (MZL). ZYNLONTA® demonstrated a 48.3% overall response rate and a 24.8% complete response rate, with a median time to complete response of 1.5 months and a manageable safety profile. The pipeline also includes a PSMA-targeting ADC candidate, currently advancing through IND-enabling activities, featuring a differentiated exatecan-based payload and novel hydrophilic linker. ADC Therapeutics SA continues to seek research collaborations for its next-generation ADC programs. You can access the full presentation through the link below: [Read the full presentation](https://docs.publicnow.com/786692C3F5E45C6C58FD5162CE8A637A05F3E439)
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.